Human application of engineered chimeric antigen receptor (CAR) T-cells
AssigneeBoard of Regents, The University of Texas System
InventorsLaurence JN Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
Claims31
An engineered cell comprising:
- (a) a chimeric antigen receptor (CAR);
- and
- (b) a fusion protein comprising IL-15 and IL-15Rα.
An IL-15, IL-15Rαfusion protein comprising an amino acid sequence which is at least 90% identical to SEQ ID NO:
- 6.
A polynucleotide comprising a DNA sequence encoding an IL-15, IL-15Rαfusion protein which is at least 90% identical to SEQ ID NO:
- 6.
An engineered cell comprising DNA encoding:
- (a) a chimeric antigen receptor (CAR);
- and
- (b) a fusion protein comprising IL-15 and IL-15Rα.
Dependencies are inferred from the claim text.